Skip to main content

Table 7 Adverse effects according to the value of the initial and maximal trough concentration (Cmin)

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Adverse effects No. of patients with initial Cmin P-value No. of patients with maximal Cmin P-value
< 20 μg/mL (n = 245) ≥20 μg/mL (n = 267) < 20 μg/mL (n = 235) ≥20 μg/mL (n = 277)
Nephrotoxicity on the 4th day 7 (2.9%) 9 (3.4%) 0.739 7 (3.0%) 9 (3.2%) 0.861
Nephrotoxicity at the end of therapy 19 (7.8%) 21 (7.9%) 0.963 17 (7.2%) 23 (8.3%) 0.653
Hepatotoxicity on the 4th day 4 (1.6%) 4 (1.5%) 1.000 4 (1.7%) 4 (1.4%) 1.000
Hepatotoxicity at the end of therapy 7 (2.9%) 4 (1.5%) 0.366 7 (3.0%) 4 (1.4%) 0.360